Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
Stock Information for Palladyne AI Corp.
Loading
Please wait while we load your information from QuoteMedia.